Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Work In Process (2022 - 2024)

Historic Work In Process for BioXcel Therapeutics (BTAI) over the last 3 years, with Q2 2024 value amounting to $387000.0.

  • BioXcel Therapeutics' Work In Process changed N/A to $387000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $387000.0, marking a year-over-year change of. This contributed to the annual value of $651000.0 for FY2023, which is 805.08% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Work In Process stood at $387000.0 for Q2 2024.
  • BioXcel Therapeutics' 5-year Work In Process high stood at $708000.0 for Q4 2022, and its period low was $122000.0 during Q3 2022.
  • For the 3-year period, BioXcel Therapeutics' Work In Process averaged around $447000.0, with its median value being $403000.0 (2022).
  • Over the last 5 years, BioXcel Therapeutics' Work In Process had its largest YoY gain of 39590.16% in 2023, and its largest YoY loss of 805.08% in 2023.
  • Over the past 3 years, BioXcel Therapeutics' Work In Process (Quarter) stood at $708000.0 in 2022, then dropped by 8.05% to $651000.0 in 2023, then plummeted by 40.55% to $387000.0 in 2024.
  • Its last three reported values are $387000.0 in Q2 2024, $253000.0 for Q1 2024, and $651000.0 during Q4 2023.